Usk Therapeutics Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 07-12-2024
- Paid Up Capital ₹ 1.00 M
as on 07-12-2024
- Company Age 3 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Revenue %
(FY 2023)
- Profit 211.69%
(FY 2023)
- Ebitda 255.79%
(FY 2023)
- Net Worth 274.49%
(FY 2023)
- Total Assets 441.72%
(FY 2023)
About Usk Therapeutics
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Ramakrishna Madakala, Puchalapalli Sankeerthi, Sadu Kameswari, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24290KA2021PTC152293
- Company No.
152293
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Sep 2021
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Usk Therapeutics?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sadu Kameswari  | Managing Director | 27-Sep-2021 | Current |
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Ramakrishna Madakala | Director | 27-Sep-2021 | Current |
| Puchalapalli Sankeerthi | Director | 27-Sep-2021 | Current |
| Sobha Velamuru | Director | 27-Sep-2021 | Current |
| Katakam Ushasree | Director | 27-Sep-2021 | Current |
Financial Performance and Corporate Structure Insights of Usk Therapeutics.
Usk Therapeutics Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 211.69% increase in profit. The company's net worth Soared by an impressive increase of 274.49%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Usk Therapeutics?
In 2023, Usk Therapeutics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Krishnasasi Health Care Private LimitedActive 7 years 11 monthsRamakrishna Madakala is a mutual person
- Sai Siddartha Super Speciality Hospitals LlpActive 1 year 4 months
Katakam Ushasree is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Usk Therapeutics?
Unlock and access historical data on people associated with Usk Therapeutics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Usk Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Usk Therapeutics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
